Chemical Intermediate Ibrutinib Powder CAS 936563-96-1 Anti-Cancer Ibrutinib

Basic Information

Product Overview

Ibrutinib is an orally available, small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity.

• Inhibition of BTK Activity: By covalently binding to the BTK active site, ibrutinib irreversibly inhibits BTK activity, thereby blocking the B-cell receptor (BCR) signaling pathway.
• Suppression of Tumor Cell Growth and Survival: Inhibition of BTK activity disrupts the survival and proliferation of malignant B cells, leading to tumor cell apoptosis and reduction in tumor burden.
• Modulation of Immune Response: Ibrutinib also affects the immune system by inhibiting the function of various immune cells, which may contribute to its therapeutic effects in autoimmune diseases.

• Oncological Treatment: Approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It is used as a monotherapy or in combination with other agents.
• Research and Development: Utilized in preclinical and clinical research to investigate its therapeutic potential in various B-cell malignancies and autoimmune diseases.
• Pharmaceutical Industry: Employed as a key active ingredient in the formulation of pharmaceutical products for the treatment of oncology conditions.

Related Products List